New Zealand - engelsk - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 0.56 mg/ml equivalent to 0.5 mg/ml octreotide base - solution for injection - 0.5 mg/ml - active: octreotide acetate 0.56 mg/ml equivalent to 0.5 mg/ml octreotide base excipient: lactic acid mannitol sodium bicarbonate water for injection

Malta - engelsk - Medicines Authority

novartis pharmaceuticals uk limited - octreotide 0.5 mg/ml - solution for infusion or injection

Malta - engelsk - Medicines Authority

novartis pharmaceuticals uk limited - octreotide 0.2 mg/ml - solution for infusion or injection

Malta - engelsk - Medicines Authority

novartis pharmaceuticals uk limited - octreotide 10 mg - powder and solvent for suspension for injection

Malta - engelsk - Medicines Authority

novartis pharmaceuticals uk limited - octreotide 20 mg - powder and solvent for suspension for injection

Malta - engelsk - Medicines Authority

novartis pharmaceuticals uk limited - octreotide 30 mg - powder and solvent for suspension for injection

USA - engelsk - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - octreotide 50 ug in 1 ml - sandostatin injection is indicated to reduce blood levels of growth hormone (gh) and insulin growth factor-1 (igf-1; somatomedin c) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. sandostatin injection is indicated for treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. sandostatin injection is indicated for the treatment of the profuse watery diarrhea associated with vasoactive intestinal peptide tumors (vipomas)-secreting tumors. improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with sandostatin injection; these trials were not optimally designed to detect such effects. sensitivity to this drug or any of its components. risk summary the limited data with sandostatin injection in pregnant women are insufficient to inform a drug-associated risk for

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide -

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 11.2mg equivalent to octreotide 10 mg;   - powder for injection - 10 mg - active: octreotide acetate 11.2mg equivalent to octreotide 10 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas